Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Immunomedics, Inc. (IMMU)


Recently stock market analysts have updated their consensus ratings on shares of Immunomedics, Inc. (IMMU).

Most recent broker ratings

10/06/2016 – Immunomedics, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 5.5 price target on the stock.

06/21/2016 – Immunomedics, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

07/29/2015 – Immunomedics, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer.

09/30/2014 – Immunomedics, Inc. had its “buy” rating reiterated by analysts at Panmure Gordon. They now have a USD 150 price target on the stock.

08/27/2014 – Immunomedics, Inc. was downgraded to “neutral” by analysts at R. F. Lafferty. They now have a USD 4 price target on the stock.

01/08/2014 – Chardan Capital began new coverage on Immunomedics, Inc. giving the company a “buy” rating. They now have a USD 9 price target on the stock.

Immunomedics, Inc. has a 50 day moving average of 2.89 and a 200 day moving average of 3.03. The stock’s market capitalization is 208.03M, it has a 52-week low of 1.61 and a 52-week high of 5.44.

The share price of the company (IMMU) was down -2.25% during the last trading session, with a high of 2.30 and the volume of Immunomedics, Inc. shares traded was 1224132.